<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789867</url>
  </required_header>
  <id_info>
    <org_study_id>cro851</org_study_id>
    <nct_id>NCT00789867</nct_id>
  </id_info>
  <brief_title>Single Dose of pGM169/GL67A in CF Patients</brief_title>
  <official_title>Evaluation of Safety and Gene Expression With a Single Dose of pGM169/GL67A Administered to the Nose and Lung of Individuals With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to assess safety, tolerability and gene expression after a single
      dose of non-viral CFTR gene therapy (pGM169/GL67A) administered to the nose and lungs of
      patients with cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is designed as single administration to nose and lung. Initially, in Part A, 3
      patients will be dosed individually one week apart with 10 ml (26.5mg pDNA) via nebuliser and
      a nasal dose equivalent to 10% of this (based on relative surface area calculations:
      conducting airways approximate 540 cm2; nasal epithelium from both nostrils approximately 40
      cm2). Based on our previous study, we do not expect any side effects of the nasal dose, but
      we are taking this opportunity, as this group will not be undergoing bronchoscopic efficacy
      measures, to assess gene transfer to the nasal epithelium. A further group of 3 patients will
      then be treated in exactly the same way with 20 ml nebulised and a 2 ml nasal dose.

      Subsequently, patients will receive doses of 2 ml (nasal) and 20 ml (nebulised). These
      patients will undergo more intensive monitoring for gene expression both before and after
      administration.

      In Part B of the protocol, we will test combinations of delivery conditions and dose in an
      attempt to identify the maximal tolerated dose. We may also use Ibuprofen or Prednisolone in
      standard clinical doses around the dosing period to reduce the inflammatory response.
      Delivery conditions include: standard nebulisation (each 5 ml over 25 minutes as in Part A),
      slow (each 5 ml over 75-150 minutes) and divided (standard rate delivery with a period of up
      to 6 hours between aliquots). With these conditions we will test the following doses until a
      tolerable dose is reached: 20 ml (no standard delivery as sufficient data already available
      from Part A); 10 ml; 5 ml; 2.5 ml. Each dosing strategy will initially be performed in a
      cohort of 3 patients although numbers may need to be increased to 6 if data are inconclusive.
      Once a satisfactory Single dose of pGM169/GL67A in CF patients; cro851 Version 10; 16.08.2010
      10 dose and nebulisation strategy has been identified, the numbers receiving this will be
      increased to 6. The maximum number of patients recruited to this arm of the study will be 30.
      Part B will also allow either these subjects or others to receive a 2 ml nasal dose with both
      pre and post-measurements of nasal PD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body Maximum Temperature</measure>
    <time_frame>6-8h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Leukocytes</measure>
    <time_frame>8h</time_frame>
    <description>Blood leukocytes measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Neutrophils</measure>
    <time_frame>8h</time_frame>
    <description>Blood neutrophils measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 Relative % Drop</measure>
    <time_frame>8h</time_frame>
    <description>FEV1 relative % drop measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FVC Relative % Drop</measure>
    <time_frame>6h</time_frame>
    <description>FVC relative % drop measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung Clearance Index - LCI</measure>
    <time_frame>8h</time_frame>
    <description>Lung clearance index measure is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout technique.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>20ml pGM169/GL67A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10ml pGM169/GL67A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5ml pGM169/GL67A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pGM169/GL67A</intervention_name>
    <description>Received a nebulized dose via an breath-actuated nebulizer</description>
    <arm_group_label>10ml pGM169/GL67A</arm_group_label>
    <arm_group_label>20ml pGM169/GL67A</arm_group_label>
    <arm_group_label>5ml pGM169/GL67A</arm_group_label>
    <other_name>5ml pGM169/GL67A, 10ml pGM169/GL67A and 20ml pGM169/GL67A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis confirmed by sweat testing or genetic analysis

          -  Males and females aged 16 years and above

          -  Forced expiratory volume in the 1st second (FEV1) &gt; 60% predicted values

          -  Clinical stability at entry

          -  Prepared to take effective contraceptive precautions for the duration of their
             participation in the study and for 3 months thereafter

          -  If taking regular rhDNase (pulmozyme) is willing, and considered able by independent
             medical carers, to withhold treatment for 24 hours before and 24 hours after the gene
             therapy dose

          -  Written informed consent obtained

          -  Permission to inform GP of participation in study

        Exclusion Criteria:

          -  Infection with Burkholderia cepacia complex organisms or MRSA

          -  Significant nasal pathology including polyps, clinically-significant rhinosinusitis,
             or recurrent severe epistaxis (nose bleeds)

          -  Acute upper respiratory tract infection within the last 2 weeks

          -  Previous spontaneous pneumothorax without pleurodesis

          -  Recurrent severe haemoptysis

          -  Current smoker

          -  Significant comorbidity including:

               1. Moderate/severe CF liver disease

               2. Significant renal impairment

               3. Significant coagulopathy

          -  Receiving 2nd line immunosuppressant drugs such as methotrexate, cyclosporine,
             intravenous immunoglobulin preparations

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Alton</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane C Davies</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uta Griesenbach</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steve Hyde</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deborah Gill</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Porteous</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chris Boyd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alastair Innes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edinburgh University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.cfgenetherapy.org.uk/</url>
    <description>UK CF Gene Therapy Consortium website</description>
  </link>
  <reference>
    <citation>Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999 Mar 20;353(9157):947-54.</citation>
    <PMID>10459902</PMID>
  </reference>
  <results_reference>
    <citation>Alton EW, Boyd AC, Porteous DJ, Davies G, Davies JC, Griesenbach U, Higgins TE, Gill DR, Hyde SC, Innes JA; UK Cystic Fibrosis Gene Therapy Consortium *. A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trial. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1389-92. doi: 10.1164/rccm.201506-1193LE.</citation>
    <PMID>26623687</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>May 23, 2019</results_first_submitted>
  <results_first_submitted_qc>January 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single dose</keyword>
  <keyword>Pilot</keyword>
  <keyword>Safety</keyword>
  <keyword>Gene expression</keyword>
  <keyword>Tolerability</keyword>
  <keyword>CFTR gene</keyword>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Non-viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>20 ml pGM169/GL67A</title>
          <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="P2">
          <title>10ml pGM169/GL67A</title>
          <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="P3">
          <title>5ml pGM169/GL67A</title>
          <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>20ml pGM169/GL67A</title>
          <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="B2">
          <title>10ml pGM169/GL67A</title>
          <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="B3">
          <title>5ml pGM169/GL67A</title>
          <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" lower_limit="17.3" upper_limit="50.1"/>
                    <measurement group_id="B2" value="33.2" lower_limit="16.4" upper_limit="61.6"/>
                    <measurement group_id="B3" value="32.6" lower_limit="24.3" upper_limit="46.4"/>
                    <measurement group_id="B4" value="27.4" lower_limit="16.4" upper_limit="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Body Maximum Temperature</title>
        <time_frame>6-8h</time_frame>
        <population>A lower number of participants due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>20ml pGM169/GL67A</title>
            <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>10ml pGM169/GL67A</title>
            <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O3">
            <title>5ml pGM169/GL67A</title>
            <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Body Maximum Temperature</title>
          <population>A lower number of participants due to missing data</population>
          <units>celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.6" spread="0.5"/>
                    <measurement group_id="O2" value="38.0" spread="0.7"/>
                    <measurement group_id="O3" value="37.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Leukocytes</title>
        <description>Blood leukocytes measure</description>
        <time_frame>8h</time_frame>
        <population>A lower number of participants due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>20ml pGM169/GL67A</title>
            <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>10ml pGM169/GL67A</title>
            <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O3">
            <title>5ml pGM169/GL67A</title>
            <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Leukocytes</title>
          <description>Blood leukocytes measure</description>
          <population>A lower number of participants due to missing data</population>
          <units>x1000000000 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="3.2"/>
                    <measurement group_id="O2" value="14.1" spread="4.5"/>
                    <measurement group_id="O3" value="12.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Neutrophils</title>
        <description>Blood neutrophils measures</description>
        <time_frame>8h</time_frame>
        <population>A lower number of participants due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>20ml pGM169/GL67A</title>
            <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>10ml pGM169/GL67A</title>
            <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O3">
            <title>5ml pGM169/GL67A</title>
            <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Neutrophils</title>
          <description>Blood neutrophils measures</description>
          <population>A lower number of participants due to missing data</population>
          <units>1000000000/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="3.4"/>
                    <measurement group_id="O2" value="11.3" spread="4.1"/>
                    <measurement group_id="O3" value="9.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Relative % Drop</title>
        <description>FEV1 relative % drop measure</description>
        <time_frame>8h</time_frame>
        <population>A lower number of participants due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>20ml pGM169/GL67A</title>
            <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>10ml pGM169/GL67A</title>
            <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O3">
            <title>5ml pGM169/GL67A</title>
            <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Relative % Drop</title>
          <description>FEV1 relative % drop measure</description>
          <population>A lower number of participants due to missing data</population>
          <units>% of drop</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="9.3"/>
                    <measurement group_id="O2" value="17.5" spread="7.8"/>
                    <measurement group_id="O3" value="16.8" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>FVC Relative % Drop</title>
        <description>FVC relative % drop measure</description>
        <time_frame>6h</time_frame>
        <population>A lower number of participants due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>20ml pGM169/GL67A</title>
            <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O2">
            <title>10ml pGM169/GL67A</title>
            <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O3">
            <title>5ml pGM169/GL67A</title>
            <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Relative % Drop</title>
          <description>FVC relative % drop measure</description>
          <population>A lower number of participants due to missing data</population>
          <units>% drop</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" spread="2.9"/>
                    <measurement group_id="O2" value="13.7" spread="2.2"/>
                    <measurement group_id="O3" value="14.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Lung Clearance Index - LCI</title>
        <description>Lung clearance index measure is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout technique.</description>
        <time_frame>8h</time_frame>
        <population>A lower number of participants due to missing data</population>
        <group_list>
          <group group_id="O1">
            <title>20ml pGM169/GL67A</title>
            <description>Received a nebulized dose 20ml via an breath-actuated nebulizer nebulizer</description>
          </group>
          <group group_id="O2">
            <title>10ml pGM169/GL67A</title>
            <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
          </group>
          <group group_id="O3">
            <title>5ml pGM169/GL67A</title>
            <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Lung Clearance Index - LCI</title>
          <description>Lung clearance index measure is a measure of abnormal ventilation distribution derived from the multiple breath inert gas washout technique.</description>
          <population>A lower number of participants due to missing data</population>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.3"/>
                    <measurement group_id="O2" value="0.32" spread="0.1"/>
                    <measurement group_id="O3" value="0.32" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>20ml pGM169/GL67A</title>
          <description>Received a nebulized dose 20ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="E2">
          <title>10ml pGM169/GL67A</title>
          <description>Received a nebulized dose 10ml via an breath-actuated nebulizer</description>
        </group>
        <group group_id="E3">
          <title>5ml pGM169/GL67A</title>
          <description>Received a nebulized dose 5ml via an breath-actuated nebulizer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Injury in luvula sustained from pressure of tube during bronchoscopy 03/04/2009</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Mild self limiting influenza like systemic response</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samia Soussi</name_or_title>
      <organization>Imperial College</organization>
      <phone>0207 594 7980</phone>
      <email>s.soussi@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

